BMJ Open Lower levels of high-density lipoprotein cholesterol in urban Africans presenting with communicable versus non-communicable forms of heart disease: the 'Heart of Soweto' hospital registry study

Jasmine G Lyons,^{1,2} Karen Sliwa,^{3,4} Melinda J Carrington,^{1,4,5} Frederick Raal,⁶ Sandra Pretorius,³ Friedrich Thienemann,^{3,7,8} Simon Stewart^{1,3,4,5}

To cite: Lyons JG, Sliwa K, Carrington MJ, *et al.* Lower levels of high-density lipoprotein cholesterol in urban Africans presenting with communicable versus non-communicable forms of heart disease: the 'Heart of Soweto' hospital registry study. *BMJ Open* 2014;**4**: e005069. doi:10.1136/bmjopen-2014-005069

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2014-005069>).

Received 17 February 2014
Revised 22 June 2014
Accepted 24 June 2014

CrossMark

For numbered affiliations see end of article.

Correspondence to
Professor Simon Stewart;
simon.stewart@bakeridi.edu.au

ABSTRACT

Objectives: To investigate if urban Africans displayed lower levels of atheroprotective high-density lipoprotein cholesterol (HDLc) when presenting with communicable versus non-communicable forms of heart disease (HD) as both acute infection and chronic inflammation reduce HDLc levels.

Design: Hospital registry of 5328 de novo cases of HD over a 3-year period.

Setting: Cardiology Unit, Baragwanath Hospital in Soweto, South Africa.

Participants: A total of 1199 patients of African descent (59% women; 57.0±13.4 years) had fasting blood lipid levels (total cholesterol (TC), triglyceride, HDLc and low-density lipoprotein cholesterol (LDLc)) documented on admission. Serum inflammatory marker C reactive protein (CRP) was measured in a subset of 367 patients (31% of cases).

Main outcome measures: Lipid profiles were compared according to prespecified classification of non-communicable (eg, hypertensive HD) versus communicable (eg, rheumatic HD) HD. Low HDLc was defined as <1.0 mmol/L for men and <1.2 mmol/L for women, according to applicable South African Clinical Guidelines.

Results: Overall 694 (58%) of those presenting with HD had low HDLc levels; 344 of 678 (51%) and 350 of 521 (67%) for non-communicable and communicable, respectively ($p<0.001$). Comparatively, overall prevalence of high TC was 32% and high LDLc was 37%. On an adjusted basis, those with non-communicable HD were more likely to record a low HDLc relative to non-communicable presentations (odds ratio (OR) 1.91, 95% CI 1.42 to 2.57; $p<0.001$). There was a strong relationship between low HDLc and higher levels of CRP, but only in women.

Conclusions: Despite largely favourable lipid profiles, there are clear differences according to aetiology of underlying HD in urban Africans, with younger patients with communicable HD having particularly low levels of HDLc. Appropriate prospective evidence is needed to

Strengths and limitations of this study

- We report a high prevalence of low high-density lipoprotein cholesterol (HDLc) in de novo presentations of both communicable heart disease and non-communicable heart disease, with a greater prevalence in those with communicable heart disease.
- The study cohort is clinically very well defined; however the lipid data were obtained according to clinical presentation, which may impose systematic bias to the results.
- This hospital registry study has provided preliminary data that would support prospective investigation of longer-term dyslipidaemia patterns and their impact on heart disease incidence, both in South Africa and in other low-and-middle-income countries where the epidemiologic transition is currently underway.

determine if persistent low levels of HDLc expose patients to increased, long-term risk of atherosclerotic forms of HD. The women-only inverse association between HDLc and CRP warrants further investigation.

INTRODUCTION

Heart diseases (HDs) with infectious aetiology have long been the principal forms of cardiovascular disease (CVD) in sub-Saharan Africa. However, epidemiological transition has seen increased prevalence of non-communicable forms of HD in these populations.¹ This phenomenon is largely driven by complex, population-wide changes in demographic, social and economic status, with associated changes in lifestyle habits.^{2–4} Indicative of the tension between 'old' and

'new' forms of HD, the incidence of communicable heart disease (CD) is sustained by the devastating epidemics of HIV/AIDS, tuberculosis (TB), rheumatic heart disease (RHD) and parasitic infections with cardiac involvement,⁵⁻⁷ while in parallel, the prevalence of risk factors for non-communicable heart disease (NCD) increases.⁸

Low serum levels of high-density lipoprotein cholesterol (HDL) are consistently and independently associated with increased risk of atherosclerotic forms of CVD.⁹⁻¹⁰ However, it remains uncertain whether low HDL is causal or just a cardiovascular risk marker.¹¹ If we are to extrapolate from studies in Western and Asian populations,¹²⁻¹⁴ isolated low HDL is associated with increased risk for CVD in the long-term. There are several causes of low HDL levels, including overweight, obesity, tobacco smoking and insulin resistance/type 2 diabetes mellitus, indicative of the important role lifestyle factors have in mediating HDL levels.⁹ Additionally, low HDL is a striking consequence of abnormal lipid metabolism in infection and inflammation.¹⁵ Although it has been shown that those of African descent largely show a favourable lipid profile characterised by high HDL levels,¹⁶ it is unlikely that they can remain atheroprotective during an infected state.¹⁵ Indeed, in this setting, it is probable that increasing prevalence of modifiable/lifestyle risk factors contribute to a more advanced presentation in those with CD.⁸ We have previously reported that in the geographically compact townships that comprise Soweto in South Africa, 'old' and 'new' forms of HD are simultaneously present.⁸ While this tension exists, we have a unique opportunity to explore lipid profiles in patients presenting with non-communicable versus communicable forms of HD.

STUDY HYPOTHESES

Having shown important ethnic differences in the lipid profiles of patients of African descent presenting with HD in the urban African enclave of Soweto,¹⁶ we hypothesised that independent of age and sex, urban Africans presenting with CD will demonstrate patterns of dyslipidaemia associated with infection/inflammation, particularly suboptimal levels of HDL, versus NCD.

METHODS

Study setting and design

As described in detail previously^{8, 17} the 3500 bed Chris Hani Baragwanath Hospital (case load of >125 000 inpatients per annum) services the tertiary care needs of Soweto (population of 1.1 million) and surrounding communities. All suspected cardiac presentations are referred to the hospital's Cardiology Unit for advanced diagnostic testing and gold-standard treatments. A prospective clinical registry of all de novo presentations of the same was established in 2006 as part of the Heart of Soweto Study and represents sub-Saharan Africa's largest and most detailed study of advanced forms of HD to date.¹⁷

Participants

The 'Heart of Soweto' cohort of de novo case presentations comprised of 5328 patients. Of these, 2185 patients (40%) had a documented fasting lipid profile (serum total cholesterol (TC) level, triglyceride (TG), HDL and calculated low-density lipoprotein cholesterol (LDL)¹⁸ undertaken at Baragwanath Hospital on-site pathology). None of the patients were on lipid lowering agents at the time of presentation, as this medication can only be prescribed at the tertiary institution. However, some of the patients had been placed on anti-hypertensive medication prior to their first assessment at the Cardiac Clinic at Baragwanath Hospital. Moreover, only a small number of patients (39 cases) had been prescribed antiretroviral therapy (ART) on presentation. All patients provided informed consent.

Study data

A complete list of study data captured by the registry, comprising basic sociodemographic (including self-reported ethnicity, years of education and determining if the patient was born in Soweto) and advanced clinical profiling, has been described previously.^{8, 17} The registry captured all advanced clinical investigative procedures (eg, coronary angiography, which was undertaken in all people diagnosed with coronary artery disease (CAD)). Echocardiography (performed on all patients) criteria used in the study have been described in detail previously.^{8, 17}

Case classifications

Adjudication and classification of communicable and non-communicable presentations of HD in this cohort have been previously described.⁸ After exclusion of those with uncomplicated hypertension (ie, without evidence of cardiac dysfunction, n=380) or other non-modifiable aetiologies (eg, congenital disorders), 1199 patients of African descent (22% of the total 'Heart of Soweto' cohort) were included in this analysis. Contributory diagnoses for NCD were predominantly hypertensive heart failure (HT-HF) and CAD (without HIV). CD was predominantly classified as HIV-dilated cardiomyopathy (HIV-DCMO), HIV-pulmonary hypertension, TB pericardial disease and pericarditis due to other infections.

Risk factor definition

Optimum lipid levels and treatment goals with established CVD were defined according to international guidelines⁹ adopted by the Lipid and Atherosclerosis Society of South Africa and the South African Heart Association—high TC: >4.5 mmol/L, high TGs: >1.7 mmol/L, high LDL: >2.5 mmol/L and low HDL: <1.0 for men and <1.2 mmol/L for women.¹⁹ Other risk factors were measured on a clinical basis, as previously described.¹⁷ Anthropometric measurements were available for calculation of body mass index (BMI, kg/m²) in 854 (71%) cases, the low reporting rate restricted to

ambulatory patients. Obesity was defined as BMI ≥ 30 kg/m². Serum C reactive protein (CRP) was measured in a subset of 367 patients (31% of all cases) if clinically indicated (eg, suspected infection). Patients were stratified into clinically relevant CRP categories,²⁰ as defined by Dhingra *et al.*²¹ Patients with a CRP of 1 mg/L (n=19) were used as reference group and compared with medium (1.1–3.0 mg/L, n=26), high (3.1–10.0 mg/L, n=83) and very high (>10.0 mg/L, n=239) CRP categories.

Statistical analyses

Normally distributed continuous data are presented as the mean $\pm$ SD and non-Gaussian distributed variables as the median (IQR). Categorical data are presented as sample number and percentages. For group comparisons, we initially used χ^2 analysis with calculation of odds ratios (ORs) with 95% CIs presented were appropriate for discrete variables, and independent t tests for normally distributed continuous variables and Mann-Whitney U test for non-parametric continuous variables. Multiple logistic regression analyses (entry model) were used to derive age and sex adjusted ORs (and BMI in some analyses, as described) for the risk of presenting with clinically relevant variables (primarily dyslipidaemia profiles), according to CD HD relative to NCD diagnosis. Significance was accepted at the two-sided level of $p < 0.05$.

RESULTS

Clinical and demographic profile

Table 1 shows the sociodemographic and clinical profile of this cohort according to cardiac aetiology. Those presenting with NCD (n=678, 56.5% of cohort) were older and had higher BMI and mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) than those with CD (n=521, 43.5%; all comparisons $p < 0.001$). Overall, 76 (6%) were confirmed HIV positive: 15 (2%) and 61 (12%) patients were confirmed HIV positive in NCD and CD groups, respectively ($p < 0.001$). Apart from higher BMIs in women (30.6 $\pm$ 6.9 vs 26.7 $\pm$ 5.5 kg/m² in men, $p < 0.001$) there were no significant differences between sexes with respect to other clinical parameters. To this, the prevalence of obesity in women was 50% as compared with men (26%), $p < 0.001$.

Aetiology of HD (primary diagnosis)

Overall, the most prevalent primary diagnoses were HT-HF (n=461, 38%), DCMO (n=178, 15%) and CAD (n=157, 12%). In those classified as NCD, HT-HF was the main primary diagnosis (n=461, 68%), along with CAD (without concurrent HIV infection; n=157, 23%). DCMO (n=178, 34%), right HF (n=92, 18%) and right HD (n=63, 12%) and other forms of primary valve disease (n=71, 14%), were the most common diagnoses in those classified with communicable forms of HD.

Lipid profiles

Those with CD have significantly lower TC, LDLC and HDLC compared with patients with NCD (table 1 and figure 1, $p < 0.001$ for all comparisons). Overall, women had significantly higher TC (4.2 $\pm$ 1.3 vs 3.8 $\pm$ 1.2 mmol/L, $p < 0.001$), LDLC (2.4 $\pm$ 1.0 vs 2.2 $\pm$ 1.0 mmol/L, $p < 0.01$) and HDLC compared with men (1.2 $\pm$ 0.5 vs 1.0 $\pm$ 0.5 mmol/L, $p < 0.001$). This gender difference did not extend to TGs (1.1(0.4–1.8) vs 1.1(0.4–1.8) mmol/L, $p = 0.7$) nor TC:HDLC ratio (4.2 $\pm$ 3.1 vs 4.3 $\pm$ 2.7 mmol/L, $p = 0.6$). Lipid ratios were calculated and compared (table 1). There were no significant differences between aetiology groups for either TC:HDL or TG:HDL groups. However LDL:HDL ratios were significantly higher in the communicable group.

Levels of TC (figure 1A), HDLC (figure 1B) and LDLC (figure 1C) were significantly higher in women with NCD (figure 1). However, in those diagnosed with CD, small, but significant, differences were observed only for TC and HDLC, not LDL (figure 1). Overall, prevalence of dyslipidaemia varied from 18% of patients with high TGs to 58% with low HDLC (table 1 and figure 2). Consistent with the decrease observed with the actual levels, prevalence of high TC and high LDLC was increased in those with NCD aetiologies while low HDLC levels prevalence was higher in those with CD (table 1 and figure 2). There were no patients with TG levels >4.5 mmol/L (range 0.1–3.8 mmol/L) which makes use of the Friedewald equation suitable for this cohort.¹⁸

Table 2 shows independent associations between relevant socioeconomic, demographic and clinical variables and CD aetiology, relative to those presenting with NCD. The effect of HD aetiology on low HDLC dyslipidaemia was strong and consistent: adjusting for age, sex and BMI of patients, those with forms of CD were significantly more likely to record a low HDLC relative to those presenting with NCD (table 2, $p < 0.001$) and less likely to record high TC and LDLC (table 2). Patients with CD were less likely to record high TG levels (OR 0.65, 95% CI 0.51 to 0.84, $p < 0.05$) compared to those with NCD.

CRP subset analysis

Overall, there was no significant difference in CRP levels between aetiology groups (table 1). The proportion of confirmed HIV cases in this CRP subset analysis was 7% (n=27). Of those, 23 were in the very high-risk category. There was also no association between CRP-derived risk categories and high TC, LDLC or TGs (data not shown). However, the risk of having low HDLC increased with increasing CRP levels. In age and sex-adjusted analyses, those with medium risk (OR 2.73, 95% CI 0.68 to 10.89, $p = 0.16$), high risk (OR 4.98, 95% CI 1.46 to 17.00, $p = 0.01$) and very high risk (OR 6.37, 95% CI 1.97 to 20.57, $p < 0.01$) CRP levels were significantly more likely to record a low HDLC relative to those in the low risk CRP group. In addition, when stratified by sex, a

Table 1 Clinical and demographic profile according to heart disease aetiology.

	All cases n=1199	Non-communicable n=678 (57%)	Communicable n=521 (43%)	p Value
Demographic profile				
Mean age (years)	58.3±14.0	60.1±13.1	55.9±14.9	<0.001
Women	701 (59%)	403 (59%)	298 (57%)	0.44
<6 years formal education	582 (49%)	335 (49%)	247 (47%)	0.52
Soweto origin	562 (47%)	327 (48%)	235 (45%)	0.29
Clinical presentation				
Total cholesterol (mmol/L)	4.0±1.4	4.3±1.3	3.7±1.2	<0.001
HDLc (mmol/L)	1.1±0.5	1.2±0.5	1.0±0.5	<0.001
Median triglycerides (mmol/L)*	1.1 (0.8, 1.5)	1.1 (0.8, 1.6)	1.0 (0.7, 1.3)	<0.001
LDLc (mmol/L)	2.4±1.0	2.5±1.0	2.2±0.9	<0.001
TC : HDLc ratio	4.3±3.0	4.2±3.1	4.4±2.7	0.27
LDL : HDLc ratio	2.5±1.1	2.5±1.0	2.7±1.1	0.36
TG : HDLc ratio*	1.1 (0.7, 1.7)	1.0 (0.7, 1.7)	1.1 (0.7, 1.8)	0.12
Median serum CRP (mg/L)*	19 (7.0, 45.0)	16.8 (6.6, 41.5)	20.5 (7.8, 55.9)	0.25
Systolic BP (mm Hg)	135±29	143±29	126±26	<0.001
Diastolic BP (mm Hg)	78±16	80±16	74±16	<0.001
BMI (kg/m ²)	29.0±6.7	30.3±6.7	27.2±6.2	<0.001
Prevalence of dyslipidaemia (n, %)				
High total cholesterol (>5 mmol/L)	378 (32%)	266 (39%)	112 (22%)	<0.001
Low HDLc (<1 in men and <1.2 mmol/L in women)	694 (58%)	344 (51%)	350 (67%)	<0.001
High LDLc (>2.5 mmol/L)	446 (37%)	291 (43%)	155 (30%)	<0.001
High triglycerides (>1.7 mmol/L)	215 (18%)	143 (21%)	72 (14%)	0.001
Prevalence of other risk factors (n, %)				
Obese (BMI >30 kg/m ²)	344 (40%)	237 (48%)	107 (30%)	<0.001
Type 2 diabetes	98 (8%)	71 (11%)	27 (5%)	<0.001
Past or current smoker	566 (47%)	321 (47%)	245 (47%)	0.95
Family history of CVD	466 (39%)	286 (42%)	180 (35%)	0.01
Confirmed HIV-positive cases	76 (6%)	15 (2%)	61 (12%)	<0.001

*Median (IQR) values presented, differences tested by Mann-Whitney U test.

BMI, body mass index (available in 854 cases); BP, blood pressure; CRP, C reactive protein (available in 367 cases); CVD, cardiovascular disease; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol; TG, triglycerides.

strong, positive association remained in women but was no longer apparent in men (figure 3). In women, the pattern was significant across all CRP risk categories: compared to low risk, those with medium risk (OR 12.1, 95% CI 1.21 to 120, $p=0.03$), high risk (OR 14.4, 95% CI 1.64 to 126, $p=0.02$) and very high risk (OR 23.5, 95% CI 2.81 to 197, $p=0.004$) CRP levels were all more likely to record a low HDLc. Moreover, the association was not weakened by addition of BMI into the model (BMI and CRP measurements available in only 230 cases) in overall and women-only ($n=133$) models: those with medium risk (OR 20.5, 95% CI 1.72 to 246, $p=0.02$), high risk (OR 10.6, 95% CI 1.14 to 98.8, $p=0.04$) and very high risk (OR 21.0, 95% CI 2.38 to 185, $p<0.01$) CRP levels were all more likely to record a low HDLc.

DISCUSSION

We report significant decreases in lipid levels (TC, HDLc and LDLc) and age and BMI according to non-communicable and communicable manifestations of de novo HD in urban Africans, patterns that were observed in both sexes. The high prevalence of low HDLc in more than half of all cases, but much higher in those

with CD, is most striking. In addition, it appears that gender is an effect modifier in the relationship between CRP and low HDLc in this cohort, but, importantly, the relationship remains even after adjustment for the significant confounder of adiposity.

While traditionally uncommon,²² dyslipidaemia, in particular low HDLc, is becoming more prevalent in sub-Saharan Africa.^{23–24} The low lipid levels present in the majority of cases with CD reflect the dramatic changes to lipid metabolism observed in infection and is therefore, anticipated. We acknowledge that atherogenic LDLc is also low in this setting and that low HDLc may not be indicative of particularly increased disease risk, at least in the short-term. However, we still deem this as highly clinically relevant given that even isolated low HDLc is associated with a higher risk of atherosclerotic forms of HD, a finding that has been seen in diverse populations.^{12–14} Interestingly TG levels were not significantly increased in those with communicable forms of HD, despite evidence that it can increase as part of the infectious/inflammatory metabolic milieu.¹⁵ Additionally, we speculate that the higher lipid levels in women may be the result of much higher rates of obesity (50% compared with 26% in men) as the driver

Figure 1 Sex specific lipid profiles according to heart disease aetiology. Lipid values are shown as mean±SE. p Values indicate between-sex comparisons per aetiology group (t test), **p<0.01; *p<0.05. NCD, non-communicable heart disease; CD, communicable heart disease; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Y-axis dotted lines show thresholds for high TC and LDL or low HDL (sex specific values).

of elevated TC, which has been suggested by authors of a worldwide systematic analysis on high TC.²⁵

Our interest in this phenomenon predominantly relates to the longer-term effects of low HDLC, especially when observed together with the amplified vascular risk associated with chronic infection.¹⁵ In Africa, where acute coronary syndromes are seen in a relatively young population,²⁶ we predict the very high rates of myriads of communicable diseases^{27–28} will result in more complex cases, with potentially poorer outcomes in the long-term, given the critical role of HDLC in both innate and adaptive immunity.¹⁵ While many infectious diseases (bacterial and viral) have contributed to the underlying pathology of HD reported here,⁵ dyslipidaemia associated with HIV infection has been particularly well studied. HIV-related low HDLC is likely a consequence of both the viral infection and an adverse effect of some antiretroviral treatment regimens,^{28–31} however only 39 patients of the 76 (51%) confirmed HIV positive

Figure 2 Prevalence of low high-density lipoprotein cholesterol according to heart disease aetiology. NCD, non-communicable heart disease; CD, communicable heart disease. High total cholesterol (TC) >4.5 mmol/L; Low high-density lipoprotein cholesterol (HDLC) (<1.0 mmol/L in men, <1.2 mmol/L in women). High low-density lipoprotein cholesterol (LDLC) >2.5 mmol/L; High triglycerides (TGs) >1.7 mmol/L.

were on ART at the time of presentation, representing 3% of the entire subset sample, which possibly dilutes this effect.

Our CRP subset analysis found associations between low HDLC and the pro-inflammatory marker CRP in patients with newly diagnosed HD in a sex disparate manner, with a much stronger positive association in women. Median CRP levels were also very high across all categories of HD aetiology, and are much higher than previous reports in early analyses of large cohorts²⁰ as well as South African studies,³² but reflect the clinical requirements at presentation. These high levels may also be the result of ‘multimorbidity’ observed in the cohort, given the prevalence of infectious disease (such as HIV/AIDS) as well as other lifestyle factors that can also influence CRP levels;³³ all of which may have contributed to

Table 2 Independent correlates of communicable heart disease, relative to non-communicable heart disease.

	Communicable disease	
	OR	95% CI
Women	0.91	0.72 to 1.15
Age	0.98	0.97 to 0.99**
Obesity	0.50	0.37 to 0.68***
<6 years formal education	1.11	0.88 to 1.42
Soweto origin	0.98	0.77 to 1.24
Body mass index adjusted analysis		
High TC	0.52	0.37 to 0.71***
High LDLC	0.56	0.41 to 0.76***
Low HDLC	1.91	1.42 to 2.57***
High TG	0.65	0.51 to 0.84*

Obesity BMI >30 kg/m²; High total cholesterol (TC) >4.5 mmol/L; High low-density lipoprotein (LDLC) >2.5 mmol/L; Low high-density lipoprotein (HDLC) (<1.0 mmol/L in men, <1.2 mmol/L in women). Age and sex-adjusted analysis: *p<0.05; **p<0.01; ***p<0.001.

Figure 3 Risk of low high-density lipoprotein cholesterol according to C reactive protein risk group, relative to low-risk C reactive protein group (n=367). Age-adjusted analysis. CRP=C reactive protein. **p<0.01; *p<0.05 relative to low CRP group. For CIs, please refer to the Results section.

the high levels observed. Inflammatory stress may be having a more adverse effect on HDLC in women compared to men as a result of many causes. The prognostic value of stratifying CVD risk, even at very high CRP (>10 mg/L) levels, has been demonstrated in a very large cohort of women,²⁰ and there are reports of elevated CRP in women of African descent.³⁴ We also report women as having a significantly higher BMI; obesity itself can induce a low-grade inflammatory response, however the association between low HDLC and CRP in women remained even after adjusting for BMI. While we have assumed that the exaggerated drop in HDLC in women with acute forms of CD is a consequence rather than a cause of infection, treatment of atherogenic dyslipidaemia and inflammatory markers in women are of particular clinical relevance in a setting where obesity and its antecedent behaviours are increasing.

These results underscore the need to consider multifactorial CVD risk burden that recognises that co-occurrence of infectious and non-communicable disease produces significant and complex health disparities. Certainly, the clinical strategies to protect the heart and vessels in acute infection differ from those required in chronic infection and it is unlikely that lipid measurements will form a cornerstone of treatment in such cases. However, it is important to recognise the benefits of early detection and treatment of dyslipidaemia in order to mitigate any double effect of infectious and 'lifestyle' HD risk factors in the longer term. While the epidemiological evidence is clear, the precise mechanism by which HDLC decreases atherosclerotic CVD risk remains unclear;¹¹ indeed, efforts to develop pharmacological modalities to specifically increase HDLC levels to reduce cardiovascular risk, continues to be problematic¹⁰ and we acknowledge that addressing the low HDLC observed in this cohort, in isolation, without commensurate improvements in HDLC functionality, will prove a difficult task. This does not, however, preclude the use of other therapeutic interventions that address the greater, more

complex risk presentation of cases that fall in the 'cross-over' between communicable and non-communicable diseases. For example, the polypill, which includes lipid-lowering medications, has been proposed as a viable treatment option in secondary prevention, given its relative ease of use and efficacy in low-income settings.³⁵ More so, evidence that statins also exert immunomodulatory effects, along with suggestions they may prove useful in the treatment and prevention of infections,³⁶ indicate they may have important, multifaceted clinical implications in populations such as Soweto, especially given the substantial dyslipidaemic risk associated with highly prevalent HIV infection and ART. Attempts to address prevention, management, cure and control of non-communicable and communicable forms of HD as entirely separate entities are likely to prove insufficient. This holds true on a per-patient basis as well as for any population-wide, public health approach.

There are a number of limitations that require consideration. Clinical data (other than routine echocardiography and 12-lead ECG) were obtained according to presentation. This study was not specifically designed to comprehensively delineate between specific forms of HD (resulting in variable clinical data) although this is part of clinical investigation at Baragwanath Hospital; although it should be noted HIV status is not routinely determined. The arbitrary selection of disease states into the communicable versus non-communicable groups (eg, primary valve disease) may be questioned; hence our further delineation of clearly identifiable cases of acute inflammation/infection at the point of admission. However, we would emphasise that classification was prospectively applied, the groupings are consistent with our previous reports that describe in detail the rigorous clinical criteria employed in profiling the 'Heart of Soweto' cohort, and expected gradients in lipid levels were subsequently found. Systematic bias needs to be carefully considered before attributing broad patterns in lipid profiles, as those with suspected atherosclerotic disease were more likely to have had lipid levels measured, reflecting the low number of those presenting an acute infectious form of HD (eg, patients with pericarditis). Adiposity, a major confounder of dyslipidaemia and HD, was recorded in 71% of the cohort. However, its inclusion in the regression analyses did not alter the significance of the associations. Central obesity measurements (eg, waist-to-hip ratio) may have offered greater delineation of CVD risk but data were not available. CRP was measured in just under one third of cases and related data require careful interpretation. Finally, owing to the cross-sectional design of this study we were not able to investigate the possible effect of the magnitude and timing of the contributing infection on lipid levels, beyond the data collected at admission. Given the transient, dynamic processes of lipid metabolism over the course of acute and chronic diseases, only longitudinal studies of lipid levels and subsequent outcomes can fully elucidate the clinical importance of our findings.

CONCLUSIONS

We have shown that despite largely favourable lipid profiles, there are clear differences according to underlying aetiology of HD in urban Africans however, overall low HDLC was the most prevalent metabolic abnormality observed in this cohort. Younger Africans with CD have particularly low levels of HDLC that, if maintained in the longer term, may leave them at increased risk of atherosclerotic disease. This is physiologically plausible in chronic infection; however low HDL at hospital admission could also simply reflect similarly low levels of TC/LDL and may not be indicative of increased long-term CVD risk. That uncertainty can only be resolved by well-powered studies with adequate follow-up, to provide sufficient evidence to address current gaps in evidence and, ultimately, guide clinical practice. Nevertheless, if proven, targeted prevention programmes that identify and actively manage individuals with a history of CD (particularly an active case) and with low levels of HDLC may be indicated. The alternative is an increasing burden of non-communicable forms of HD in urban African communities that is supplemented (in origin and confluence) by historical cases of communicable disease that have adversely affected protective HDLC levels (particularly in women).

Author affiliations

¹Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia

²Division of Health Sciences, University of South Australia, Adelaide, Australia

³Hatter Institute for Cardiovascular Research in Africa, Cape Heart Group and IIDMM, University of Cape Town, Cape Town, South Africa

⁴Soweto Cardiovascular Research Unit, University of the Witwatersrand, Johannesburg, South Africa

⁵Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia

⁶Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa

⁷Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa

⁸Infectious Diseases Referral Clinic, GF Jooste Hospital, Manenberg, South Africa

Acknowledgements The authors thank all the doctors, nurses and patients who participated in the registry; and Elisabeth Tshele, Bridget Phooko, Maureen Kubheka and Phutuma Mathusi who contributed to the meticulous collection and management of clinical data.

Contributors KS, MJC and SS participated in the original design of the study and supervised the collection of data. JGL prepared the first draft of the manuscript, with edits and revisions provided by all authors. FR and FT revised manuscript critically for important intellectual content. All authors had full access to all the data and read and approved the final version of the manuscript. All authors had final responsibility for the decision to submit the manuscript for publication.

Funding The 'Heart of Soweto Study' registry was supported by the University of the Witwatersrand and unconditional research grants from Adcock-Ingram, the Medtronic Foundation USA, Servier, Bayer-Schering and BHP Billiton. All authors had financial support from independent funding bodies, including University of the Witwatersrand and unconditional research grants from Adcock-Ingram, the Medtronic Foundation USA, Servier, Bayer-Schering and BHP Billiton, for the submitted work. SS, MJC and JGL are supported by the National Health and Medical Research Council of Australia [Programme Grants 320860 and 631947 and Postgraduate scholarship

586739]. JGL is supported by the National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Baker IDI is supported by the Victorian Government's Operational Infrastructure Support Programme. KS and SL are supported by the MRC South Africa and the University of Cape Town.

Competing interests None.

Patient consent Obtained.

Ethics approval The study was approved by the University of the Witwatersrand Ethical Committee and conforms to the principles outlined in the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Study data will be available on request from the corresponding author.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

1. Yusuf S, Reddy S, Ounpuu S, *et al*. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. *Circulation* 2001;104:2855–64.
2. Vorster HH. The emergence of cardiovascular disease during urbanisation of Africans. *Public Health Nutr* 2002;5:239–43.
3. Mensah GA. Descriptive epidemiology of cardiovascular risk factors and diabetes in sub-Saharan Africa. *Prog Cardiovasc Dis* 2013;56:240–50.
4. Danaei G, Singh GM, Paciorek CJ, *et al*. The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008. *Circulation* 2013;127:1493–502, 502e1–8.
5. Mocumbi AO, Sliwa K. Women's cardiovascular health in Africa. *Heart* 2012;98:450–5.
6. Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. *Eur Heart J* 2013;34:3538–46.
7. Sliwa K, Carrington MJ, Becker A, *et al*. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. *Eur Heart J* 2012;33:866–74.
8. Stewart S, Carrington M, Pretorius S, *et al*. Standing at the crossroads between new and historically prevalent heart disease: effects of migration and socio-economic factors in the Heart of Soweto cohort study. *Eur Heart J* 2011;32:492–9.
9. Chapman MJ, Ginsberg HN, Amarenco P, *et al*. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J* 2011;32:1345–61.
10. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. *Nature* 2011;473:317–25.
11. Voight BF, Peloso GM, Orho-Melander M, *et al*. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. *Lancet* 2012;380:572–80.
12. Huxley RR, Barzi F, Lam TH, *et al*. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. *Circulation* 2011;124:2056–64.
13. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. *Arterioscler Thromb Vasc Biol* 1997;17:107–13.
14. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. *J Am Coll Cardiol* 2008;51:49–55.
15. Khovidhunkit W, Kim MS, Memon RA, *et al*. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. *J Lipid Res* 2004;45:1169–96.
16. Sliwa K, Lyons JG, Carrington MJ, *et al*. Different lipid profiles according to ethnicity in the Heart of Soweto study cohort of de novo presentations of heart disease. *Cardiovasc J Afr* 2012;23:389–95.

17. Sliwa K, Wilkinson D, Hansen C, *et al.* Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. *Lancet* 2008;371:915–22.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499–502.
19. Klug E. South African dyslipidaemia guideline consensus statement. *S Afr Med J* 2012;102(3 Pt 2):178–87.
20. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. *Circulation* 2004;109:1955–9.
21. Dhingra R, Gona P, Nam BH, *et al.* C-reactive protein, inflammatory conditions, and cardiovascular disease risk. *Am J Med* 2007;120:1054–62.
22. Zoratti R. A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin? *Eur J Epidemiol* 1998;14:9–21.
23. Ulasl II, Ijoma CK, Onodugo OD. A community-based study of hypertension and cardio-metabolic syndrome in semi-urban and rural communities in Nigeria. *BMC Health Serv Res* 2010;10:71.
24. Sumner AE, Zhou J, Doumatey A, *et al.* Low HDL-cholesterol with normal triglyceride levels is the most common lipid pattern in West Africans and African Americans with metabolic syndrome: implications for cardiovascular disease prevention. *CVD Prev Contr* 2010;5:75–80.
25. Farzadfar F, Finucane MM, Danaei G, *et al.* National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. *Lancet* 2011;377:578–86.
26. Steyn K, Sliwa K, Hawken S, *et al.* Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. *Circulation* 2005;112:3554–61.
27. Tollman SM, Kahn K, Sartorius B, *et al.* Implications of mortality transition for primary health care in rural South Africa: a population-based surveillance study. *Lancet* 2008;372:893–901.
28. Adewole OO, Eze S, Betiku Y, *et al.* Lipid profile in HIV/AIDS patients in Nigeria. *Afr Health Sci* 2010;10:144–9.
29. Anastos K, Ndamage F, Lu D, *et al.* Lipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan women. *AIDS Res Ther* 2010;7:34.
30. Armstrong C, Liu E, Okuma J, *et al.* Dyslipidemia in an HIV-positive antiretroviral treatment-naïve population in Dar es Salaam, Tanzania. *J Acquir Immune Defic Syndr* 2011;57:141–5.
31. Buchacz K, Weidle PJ, Moore D, *et al.* Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. *J Acquir Immune Defic Syndr* 2008;47:304–11.
32. Ntyintyane L, Panz V, Raal FJ, *et al.* Leptin, adiponectin, and high-sensitivity C-reactive protein in relation to the metabolic syndrome in urban South African blacks with and without coronary artery disease. *Metab Syndr Relat Disord* 2009;7:243–8.
33. Nordestgaard BG. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. *Curr Opin Lipidol* 2009;20:393–401.
34. Albert MA, Glynn RJ, Buring J, *et al.* C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). *Am J Cardiol* 2004;93:1238–42.
35. Yusuf S, Islam S, Chow CK, *et al.*; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. *Lancet* 2011;378:1231–43.
36. Tleyjeh IM, Kashour T, Hakim FA, *et al.* Statins for the prevention and treatment of infections: a systematic review and meta-analysis. *Arch Intern Med* 2009;169:1658–67.